Period:
Draw Mode:
| Volume | 709,275 |
|
|||||
| News | - | ||||||
| Day High | 1.44 | Low High |
|||||
| Day Low | 1.29 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Histogen Inc | HSTO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.01 | 0.71% | 1.42 | 13:45:49 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.29 | 1.29 | 1.44 | 1.41 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,300 | 709,275 | $ 1.39 | $ 982,567 | - | 0.7603 - 9.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:52:19 | 17 | $ 1.4101 | USD |
Histogen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 6.07M | 4.27M | 4.15M | $ 3.77M | $ - | -3.37 | 7.80 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 106.79k | 1.40% |
Histogen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HSTO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.912 | 1.6201 | 0.8329 | 1.33 | 11,041,075 | 0.508 | 55.7% |
| 1 Month | 1.06 | 1.6201 | 0.8329 | 1.33 | 2,540,805 | 0.36 | 33.96% |
| 3 Months | 0.875 | 1.6201 | 0.7603 | 1.31 | 996,709 | 0.545 | 62.29% |
| 6 Months | 1.64 | 1.665 | 0.7603 | 1.28 | 565,057 | -0.22 | -13.41% |
| 1 Year | 5.40 | 9.40 | 0.7603 | 4.55 | 1,247,878 | -3.98 | -73.7% |
| 3 Years | 88.20 | 100.00 | 0.7603 | 15.49 | 1,193,463 | -86.78 | -98.39% |
| 5 Years | 88.20 | 100.00 | 0.7603 | 15.49 | 1,193,463 | -86.78 | -98.39% |
Histogen Description
| Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop. |